A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer

Annals of Oncology

Volumn 24, Issue 4, 2013, Pages 937-943

  Lee, C K ^a   Simes, R J ^a   Brown, C ^a   Gebski, V ^a   Pfisterer, J ^b   Swart, A M ^c   Berton Rigaud, D ^d   Plante, M ^e   Skeie Jensen, T ^f   Vergote, I ^g   Schauer, C ^h   Pisano, C ⁱ   Parma, G ^j   Baumann, K ^k   Ledermann, J A ^l   Pujade Lauraine, E ^m   Bentley, J ⁿ   Kristensen, G ^f   Belau, A ^o   Nankivell, M ^c   Canzler, U ^p   Lord, S J ^a   Kurzeder, C ^q   Friedlander, M ^r   more..

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF KIEL   (Germany)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d CENTRE RENÉ GAUDUCHEAU   (France)

^e LAVAL UNIVERSITY   (Canada)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h Hospital Barmherzige Brüder Graz   (Austria)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k PHILIPPS UNIVERSITY MARBURG   (Germany)

^l UNIVERSITY COLLEGE LONDON   (United Kingdom)

^m UNIVERSITÉ PARIS DESCARTES   (France)

ⁿ DALHOUSIE UNIVERSITY   (Canada)

^o UNIVERSITY OF GREIFSWALD   (Germany)

^p UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^q KLINIKEN ESSEN MITTE   (Germany)

^r PRINCE OF WALES HOSPITAL   (Australia)

more..

Author keywords

Nomogram; Overall survival; Platinum sensitivity; Prognosis; Recurrent ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; CARBOPLATIN; DOXORUBICIN; GEMCITABINE; HEMOGLOBIN; PACLITAXEL; PLATINUM COMPLEX;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CHEMOSENSITIVITY; COHORT ANALYSIS; FEMALE; FUNCTIONAL STATUS; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE CYCLE TREATMENT; NOMOGRAM; OVARY CANCER; OVERALL SURVIVAL; PATIENT CODING; PREDICTION; PRIORITY JOURNAL; RECURRENT CANCER; STATISTICAL PARAMETERS; TREATMENT RESPONSE;

EID: 84875586086     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds538     Document Type: Article

References (26)

1. Hagerty RG, Butow PN, Ellis PA et al.. Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 2004; 22: 1721-1730.
2. Lee CK, Simes RJ, Brown C et al.. Prognostic nomogram to predict progressionfree survival in patients with platinum-sensitive recurrent ovarian cancer. Br J Cancer 2011; 105: 1144-1150.
3. Rustin GJS, Quinn M, Thigpen T et al.. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 2004; 96: 487-488.
4. Tempany CMC, Zou KH, Silverman SG et al.. Staging of advanced ovarian cancer: comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Radiology 2000; 215: 761-767.
5. Panageas KS, Ben-Porat L, Dickler MN et al.. When you look matters: the effect of assessment schedule on progression-free survival. J Natl Cancer Inst 2007; 99: 428-432.
6. Marth C, Alexandre J, Hanker L et al.. Pegylated liposomal doxorubicin and carboplatin (C-PLD) versus paclitaxel and carboplatin (C-P) in platinum-sensitive ovarian cancer (OC) patients (pts): treatment at recurrence and overall survival (OS) final analysis from CALYPSO phase III GCIG trial. J Clin Oncol 2011; 29: 5052.
7. Pfisterer J, Plante M, Vergote I et al.. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006; 24: 4699-4707.
8. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-2106.
9. Cox D. Regression models and life-tables. J R Stat Soc Series B (Methodological) 1972; 34: 187-220.
10. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23: 2109-2123.
11. Newson R. Parameters behind 'nonparametric' statistics: Kendall's tau, Somers' D and median differences. Stata J 2002; 2: 45-64.
12. Pencina MJ, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157-172.
13. McNemar Q. Note on the sampling error of thee differences between correlated proportions or percentages. Psychometrika 1947; 12: 153-157.
14. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
15. Carey MS, Bacon M, Tu D et al.. The prognostic effects of performance status and quality of life scores on progression-free survival and overall survival in advanced ovarian cancer. Gynecol Oncol 2008; 108: 100-105.
16. Vickers AJ. Prediction models: revolutionary in principle, but do they do more good than harm? J Clin Oncol 2011; 29: 2951-2952.
17. Ravdin PM, Siminoff LA, Davis GJ et al.. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001; 19: 980-991.
18. Korn EL, Liu P-Y, Lee SJ et al.. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
19. Tang H, Foster NR, Grothey A et al.. Comparison of error rates in single-arm versus randomized phase II cancer clinical trials. J Clin Oncol 2010; 28: 1936-1941.
20. Lee CK, Lord SJ, Stockler MR et al.. Historical cross-trial comparisons for competing treatments in advanced breast cancer-an empirical analysis of bias. Eur J Cancer 2010; 46: 541-548.
21. Weeks JC, Cook EF, O'Day SJ et al.. Relationship between cancer patients' predictions of prognosis and their treatment preferences. JAMA 1998; 279: 1709-1714.
22. Stockler MR, Tattersall MHN, Boyer MJ et al.. Disarming the guarded prognosis: predicting survival in newly referred patients with incurable cancer. Br J Cancer 2005; 94: 208-212.
23. Glare P, Virik K, Jones M et al.. A systematic review of physicians' survival predictions in terminally ill cancer patients. Br Med J 2003; 327: 195.
24. Viganò A, Dorgan M, Bruera E et al. The relative accuracy of the clinical estimation of the duration of life for patients with end of life cancer. Cancer 1999; 86: 170-176.
25. Henderson R, Keiding N. Individual survival time prediction using statistical models. J Med Ethics 2005; 31: 703-706.
26. Konstantinopoulos PA, Spentzos D, Cannistra SA. Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 2008; 5: 577-587.